Participant may receive up to 5 cycles of FLAG-IDA chemotherapy and venetoclax, followed by up to 12 months of venetoclax maintenance therapy (if participant continues to receive it). Participant will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.